| Budget Amount *help |
¥25,090,000 (Direct Cost: ¥19,300,000、Indirect Cost: ¥5,790,000)
Fiscal Year 2015: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
Fiscal Year 2014: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
Fiscal Year 2013: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
|---|
| Outline of Final Research Achievements |
Myelin is an indispensable architecture of the central nervous system, required for saltatory conduction and for protection of neuronal cells. Clinically speaking, myelin is not only involved in demyelinating diseases such as multiple sclerosis, but also in Alzheimer's disease, Parkinson's disease, neurodegenerative diseases including ALS, psychiatric diseases including schizophrenia and major depression, or in trauma such as spinal cord injury.
In the current study, the role of myelin regeneration in these pathologies has been reconsidered, and we speculate that it is essential not only to solely induce remyelination but also provide a pathway to supply myelin-lipids to enable myelniogenesis, in which astrocytes' ketogenesis may have the most important role.
|
